Article Sidebar

PDF (Tiếng Việt)
Published: 2025-07-28
Abstract Views: 0
Views PDF (Tiếng Việt): 0
DOI: https://doi.org/10.52852/tcncyh.v192i7.3699
Issue
Vol. 192 No. 7 (2025)
Section
Các bài báo
How to Cite
Giao, N. Q., Phương, N. T., Long, L. Đức, Chi, T. K., Hảo, N. T., & Dung, Đặng T. N. (2025). 7. Serum Methadone concentration in opioid - dependent patients receiving methadone maintenance therapy. Journal of Medical Research, 192(7), 57-64. https://doi.org/10.52852/tcncyh.v192i7.3699

7. Serum Methadone concentration in opioid - dependent patients receiving methadone maintenance therapy

Nguyen Quynh Giao, Nguyen Tran Phuong, Luu Duc Long, Tran Khanh Chi, Nguyen Thi Hao, Dang Thi Ngoc Dung

Main Article Content

Abstract

Steady-state plasma methadone concentration is considered an indicator for quantifying methadone metabolism and can serve as a surrogate marker for treatment response and efficacy. We evaluated the relationship between serum drug concentration and therapeutic dose adjustment of trough serum levels. It is known that 150 - 600 ng/mL range in methadone maintenance therapy effectively suppress opioid use. Trough serum methadone concentrations in 200 patients with methadone therapy were quantified using liquid chromatography-tandem mass spectrometry (LC-MS/MS). The mean serum concentration in the study was 257.59 ± 212.62 ng/mL, showing a strong correlation with the therapeutic dose (Spearman's Rho = 0.65).

Article Details

Keywords

Trough methadone concentration, opioid dependence

References

1. The impact of OPRM1’s genetic polymorphisms on methadone maintenance treatment in opioid addicts: a systematic review - PubMed. Accessed May 13, 2025. https://pubmed.ncbi.nlm.nih.gov/29785888/.
2. Yang HC, Chu SK, Huang CL, et al. Genome-Wide Pharmacogenomic Study on Methadone Maintenance Treatment Identifies SNP rs17180299 and Multiple Haplotypes on CYP2B6, SPON1, and GSG1L Associated with Plasma Concentrations of Methadone R- and S-enantiomers in Heroin-Dependent Patients. PLoS Genet. 2016; 12(3): e1005910. doi:10.1371/journal.pgen.1005910.
3. Mouly S, Bloch V, Peoc’h K, et al. Methadone dose in heroin-dependent patients: role of clinical factors, comedications, genetic polymorphisms and enzyme activity. Br J Clin Pharmacol. 2015; 79(6): 967-977. doi:10.1111/bcp.12576.
4. Peng S, Jiang H, Du J, et al. Methadone Dosage and Plasma Levels, SNPs of OPRM1 Gene and Age of First Drug Use Were Associated With Outcomes of Methadone Maintenance Treatment. Front Genet. 2018; 9:450. doi:10.3389/fgene.2018.00450.
5. Crettol S, Déglon JJ, Besson J, et al. Methadone enantiomer plasma levels, CYP2B6, CYP2C19, and CYP2C9 genotypes, and response to treatment. Clin Pharmacol Ther. 2005; 78(6): 593-604. doi:10.1016/j.clpt.2005.08.011.
6. Goodman. The Pharmacologycal Basis of Therapeutic. 9th ed.
7. Bộ y tế. HƯỚNG DẪN điều trị thay thế nghiện các chất dạng thuốc phiện bằng thuốc methadone.
8. Loimer N, Schmid R. The use of plasma levels to optimize methadone maintenance treatment. Drug Alcohol Depend. 1992; 30(3): 241-246. doi:10.1016/0376-8716(92)90058-k.
9. Wolff K, Sanderson M, Hay AW, Raistrick D. Methadone concentrations in plasma and their relationship to drug dosage. Clin Chem. 1991; 37(2): 205-209.
10. Stewart B. Leavitt. Methadone Dosing & Safety in the Treatment of Opioid Addiction. Addict Treat.
11. Payte JT. Principles of Addiction Medicine. In: Opioid Maintenance Treatment. American Society of Addiction Medicine; 2003.
12. Chalabianloo F, Fadnes LT, Johansson KA, et al. Methadone pharmacokinetics in opioid agonist treatment: Influencing factors and clinical implications. Basic Clin Pharmacol Toxicol. 2024; 134(3): 333-344. doi:10.1111/bcpt.13975.